Invivyd Completes Enrollment in Phase 3 LIBERTY Trial of VYD2311

What happened

Invivyd announced completion of enrollment in its Phase 3 LIBERTY trial comparing VYD2311, an investigational monoclonal antibody, against an mRNA COVID-19 vaccine for safety and tolerability, and also evaluating combination use. The trial's primary endpoint assesses side effects through day 6. Initial results are expected in Q3 2026, potentially alongside data from the pivotal DECLARATION trial. This milestone advances Invivyd's next-generation candidate, which aims to offer an alternative to vaccines for COVID-19 prevention, but VYD2311 remains in development and will not contribute to near-term revenue.

Implication

The LIBERTY trial is a key catalyst for VYD2311, but meaningful commercial impact is likely years away. Investors should weigh this against immediate risks: PEMGARDA's variant susceptibility threshold, competitive threat from AstraZeneca's sipavibart, and the company's history of missing revenue targets. Positive VYD2311 data could enhance the pipeline story, but the current HOLD thesis is unchanged until results.

Thesis delta

The news incrementally supports Invivyd's pipeline narrative but does not alter the fundamental near-term thesis, which hinges on PEMGARDA's commercial ramp and variant susceptibility. The LIBERTY trial is an important read-through for VYD2311's potential, but no shift warranted until data readout.